Milestone Pharmaceuticals (NASDAQ:MIST) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a report published on Monday,Benzinga reports. HC Wainwright currently has a $25.00 price objective on the stock.

Milestone Pharmaceuticals Stock Performance

Shares of NASDAQ:MIST opened at $2.41 on Monday. The company has a market capitalization of $128.52 million, a price-to-earnings ratio of -2.98 and a beta of 1.83. The firm’s 50 day simple moving average is $2.02 and its 200 day simple moving average is $1.81. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40. Milestone Pharmaceuticals has a fifty-two week low of $1.12 and a fifty-two week high of $2.75.

Institutional Trading of Milestone Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. Jones Financial Companies Lllp raised its holdings in Milestone Pharmaceuticals by 1,000.0% during the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock worth $26,000 after buying an additional 10,000 shares during the period. National Bank of Canada FI raised its holdings in Milestone Pharmaceuticals by 163.4% during the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock worth $44,000 after buying an additional 11,600 shares during the period. PVG Asset Management Corp acquired a new stake in Milestone Pharmaceuticals during the 3rd quarter worth approximately $46,000. Atria Investments Inc raised its holdings in Milestone Pharmaceuticals by 44.4% during the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after buying an additional 12,430 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new stake in Milestone Pharmaceuticals during the 4th quarter worth approximately $73,000. 86.18% of the stock is currently owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.